TY - JOUR
T1 - Comparison of inflammation-based prognostic scores as predictors of survival outcomes in patients with germ cell tumors
AU - Yoshinaga, Kasumi
AU - Sadahira, Takuya
AU - Maruyama, Yuki
AU - Mitsui, Yosuke
AU - Iwata, Takehiro
AU - Wada, Koichiro
AU - Araki, Motoo
AU - Watanabe, Toyohiko
AU - Nasu, Yasutomo
N1 - Funding Information:
The authors thank the clinical laboratory technicians of Okayama University Hospital for their technical support.
PY - 2021
Y1 - 2021
N2 - Purpose: The aim of this study was to compare the prognostic value of pretreatment inflammation-based scoring systems in terms of overall survival (OS) and progression-free survival (PFS) in patients with germ cell tumors (GCTs) receiving bleomycin, etoposide, and cisplatin (BEP) chemotherapy. Materials and Methods: We evaluated 63 patients with GCTs retrospectively. The Glasgow prognostic score (GPS), neutrophil-to-lymphocyte ratio, prognostic index, platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), systemic immune-inflammation index, and albumin-to-globulin ratio (AGR) were measured in all patients before chemotherapy. To assess the predictive ability of each scoring system, areas under the receiver operating characteristic curve were calculated, and multivariate analysis was performed to identify associations between the predictive scores and OS. Results: Of all the inflammation-based scoring systems, the GPS had the greatest area under the curve (0.847) for predicting OS, followed by the PNI (0.829) and AGR (0.810). Kaplan–Meier analyses revealed that the GPS, PNI, and AGR were significantly associated with OS, whereas the GPS, PLR, and PNI were significantly associated with PFS. In the multivariate analysis, the GPS was an independent predictor of OS and PFS. Conclusions: We demonstrated that the GPS was the most valuable biomarker of OS and PFS in patients with GCTs.
AB - Purpose: The aim of this study was to compare the prognostic value of pretreatment inflammation-based scoring systems in terms of overall survival (OS) and progression-free survival (PFS) in patients with germ cell tumors (GCTs) receiving bleomycin, etoposide, and cisplatin (BEP) chemotherapy. Materials and Methods: We evaluated 63 patients with GCTs retrospectively. The Glasgow prognostic score (GPS), neutrophil-to-lymphocyte ratio, prognostic index, platelet-to-lymphocyte ratio (PLR), prognostic nutritional index (PNI), systemic immune-inflammation index, and albumin-to-globulin ratio (AGR) were measured in all patients before chemotherapy. To assess the predictive ability of each scoring system, areas under the receiver operating characteristic curve were calculated, and multivariate analysis was performed to identify associations between the predictive scores and OS. Results: Of all the inflammation-based scoring systems, the GPS had the greatest area under the curve (0.847) for predicting OS, followed by the PNI (0.829) and AGR (0.810). Kaplan–Meier analyses revealed that the GPS, PNI, and AGR were significantly associated with OS, whereas the GPS, PLR, and PNI were significantly associated with PFS. In the multivariate analysis, the GPS was an independent predictor of OS and PFS. Conclusions: We demonstrated that the GPS was the most valuable biomarker of OS and PFS in patients with GCTs.
KW - Germ cell tumor
KW - Glasgow prognostic score
KW - Prognostic nutritional index
UR - http://www.scopus.com/inward/record.url?scp=85099033677&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099033677&partnerID=8YFLogxK
U2 - 10.4111/icu.20200103
DO - 10.4111/icu.20200103
M3 - Article
C2 - 33314803
AN - SCOPUS:85099033677
VL - 62
SP - 47
EP - 55
JO - Investigative and Clinical Urology
JF - Investigative and Clinical Urology
SN - 2466-0493
IS - 1
ER -